目的 探討腦血疏口服液聯(lián)合丁苯酞治療急性腦梗死的臨床療效。方法 收集2015年1月—2016年1月陜西省人民醫(yī)院神經(jīng)腦科病院收治的86例急性腦梗死患者，隨機分為對照組（43例）和治療組（43例）。兩組患者均按急性腦梗死診療指南給予常規(guī)治療。對照組靜脈滴注丁苯酞氯化鈉注射液，25 mg/次，2次/d。治療組在對照組的基礎上口服腦血疏口服液，10 mL/次，3次/d。兩組患者均連續(xù)治療14 d。觀察兩組的臨床療效，比較兩組治療前后NHISS評分、Barthel指數(shù)、血清學指標。結果 治療后，對照組與治療組治療的總有效率分別為81.40%和95.35%，兩組總有效率比較差異具有統(tǒng)計學意義（P<0.05）。治療后，兩組患者NIHSS評分明顯降低，Barthel指數(shù)明顯升高，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組NIHSS評分和Barthel指數(shù)改善程度優(yōu)于對照組（P<0.05）。治療后兩組患者血清超敏C-反應蛋白（hs-CRP）、基質(zhì)金屬蛋白酶-9（MMP-9）水平較治療前明顯降低，一氧化氮（NO）、血管內(nèi)皮生長因子（VEGF）、腦源性神經(jīng)營養(yǎng)因子（BDNF）和堿性成纖維細胞生長因子（bFGF）水平均較治療前明顯增加，同組治療前后比較差異具有統(tǒng)計學意義（P<0.05）；且治療組上述血清學指標改善程度優(yōu)于對照組，兩組比較差異具有統(tǒng)計學意義（P<0.05）。結論 腦血疏口服液聯(lián)合丁苯酞治療急性腦梗死可提高患者臨床療效，改善血液流變學狀態(tài)，降低血清炎性因子水平，具有一定的臨床推廣應用價值。

Objective To explore the clinical efficacies of Naoxueshu Oral Liquid combined with butylphthalide in treatment of acute cerebral infarction. Methods Patients (86 cases) with acute cerebral infarction in Shaanxi Provincial People's Hospital from January 2015 to January 2016 were randomly divided into control (43 cases) and treatment groups (43 cases). All patients in two groups were treated with the conditional therapy according to the guidelines for diagnosis and treatment of acute cerebral infarction. Patients in the control group were iv administered with Butylphthalide and Sodium Chloride Injection, 25 mg/time, twice daily. Patients in the treatment group were po administered with Naoxueshu Oral Liquid on the basis of the control group, 10 mL/time, three times daily. The patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and NIHSS score, Barthel index, and serological indexes before and after treatment in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 81.40% and 95.35%, respectively, and there were differences between two groups (P<0.05). After treatment, NIHSS scores were obviously decreased, but Barthel indexes were increased, and the differences were statistically significant in the same group (P<0.05); The improvement of NIHSS scores and Barthel indexes in the treatment group were better than those in the control group (P<0.05). After treatment, hs-CRP and MMP-9 levels were significantly decreased, NO, VEGF, BDNF, and bFGF levels were significantly increased, and the differences were statistically significant in the same group (P<0.05); The serological indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Naoxueshu Oral Liquid combined with Butylphthalide in treatment of acute cerebral infarction can improve the clinical efficacy, hemorheological indexes, and reduce the levels of serum inflammatory factors, which has a certain clinical application value.

“步長杯”陜西省神經(jīng)病學研究基金項目（Z33）